Polypharmacology: Repurposing ceritinib
Nature Reviews Drug Discovery 16, 828 (2017).
doi:10.1038/nrd.2017.233
Author: Sarah Crunkhorn
Network-based targeting strategies represent a promising therapeutic approach for the treatment of diseases that lack strong and actionable drivers. Using an integrated phenotypic screening and phosphoproteomics strategy, Kuenzi et al. report that the FDA-approved ALK inhibitor ceritinib exhibits activity in several ALK-negative non-small-cell lung
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
More News: Drugs & Pharmacology | Non-Small Cell Lung Cancer